Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood clues could flag hidden brain risks in kids with HIV

NCT ID NCT07770568

Knowledge-focused Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This study looks at blood samples from children with HIV who started treatment very early in life, comparing them to children without HIV. Even with early treatment, these children often have lower cognitive test scores. The goal is to see if certain metabolic patterns in the blood are linked to inflammation and to thinking or memory problems. By analyzing stored plasma, researchers hope to find early warning signs that could help protect brain development.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Metabolomic NMR analysis of plasma samples (no drug or intervention given)
What this could lead to
If metabolic signatures are linked to cognitive problems, this could lead to early screening or new treatments to protect brain development in children with HIV.
What could go wrong
This is a small, retrospective pilot study, so findings may not be definitive. It only looks at stored samples and cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 128 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The children included in this study are those from the ANRS 12225 - Pediacam III cohort who participated in the ANRS 12322 - PediacamDEV study (2016 - 2017).. According to the results of the KABC II, our study population is divided in three group: Group 1: HIV-infected children on ART (N=62) Group 2: HIV-uninfected children born to HIV-positive mothers (N=31) Group 3: HIV-uninfected children born to HIV-negative mothers (N= 35) With 3 sampling points on different dates for each child, the total number of samples to be processed will be N= 384 samples.

Ages

13 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any infected or uninfected child in the ANRS 12225 Pediacam III cohort who participated in the ANRS 12322 - PediacamDev study on the evaluation of neurocognitive development and who had the results of the KABC II test (IPM and INV). * Children still followed in the ANRS cohort - Pediacam III having participated in the ANRS 12322 study - PediacamDev having results of the KABC II test (IPM and INV) and having plasma samples and never thawed in sufficient quantity (500 microliter) ; at different times of longitudinal follow-up: at 6 (±1.5) months and 12 (± 3) months, and at 108 (± 6) months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.